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Abstract
The retinoblastoma tumor suppressor (pRb) regulates cell cycle entry, progression and exit by controlling the activity of the
E2F-family of transcription factors. During cell cycle exit pRb acts as a transcriptional repressor by associating with E2F
proteins and thereby inhibiting their ability to stimulate the expression of genes required for S phase. Indeed, many tumors
harbor mutations in the RB gene and the pRb-E2F pathway is compromised in nearly all types of cancers. In this report we
show that both pRb and its interacting partners, the transcriptional factors E2F1-2-3, act as positive modulators of
detoxification pathways important for metabolizing and clearing xenobiotics—such as toxins and drugs—from the body.
Using a combination of conventional molecular biology techniques and microarray analysis of specific cell populations, we
have analyzed the detoxification pathway in murine samples in the presence or absence of pRb and/or E2F1-2-3. In this
report, we show that both pRb and E2F1-2-3 act as positive modulators of detoxification pathways in mice, challenging the
conventional view of E2F1-2-3 as transcriptional repressors negatively regulated by pRb. These results suggest that
mutations altering the pRb-E2F axis may have consequences beyond loss of cell cycle control by altering the ability of
tissues to remove toxins and to properly metabolize anticancer drugs, and might help to understand the formation and
progression rates of different types of cancer, as well as to better design appropriate therapies based on the particular
genetic composition of the tumors.
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Introduction
Organisms respond to xenobiotics -natural compounds or
artificial substances not normally present in the body such as
drugs, antibiotics, pollutants and carcinogens- by deactivating and
excreting those products via a series of enzymes located mostly in
the liver and, to a lesser extent, in the small intestine. Three sets
of enzymes contribute to the process. First, Phase I enzymes
chemically modify the xenobiotics by multiple mechanisms. Phase
II components then conjugate the products with glucuronic acid,
sulphuric acid or glutathione, to make them more soluble. Finally,
transporter members of the Phase III help to excrete the modified
components via urine or bile [1]. Phase I of the pathway is carried
out by members of the cytochrome P450 (Cyp) superfamily, a
large and diverse group of hemoproteins present in most
organisms and whose activity is responsible for almost 75% of
the total drug metabolism in higher eukaryotes [1]. Phase II
involves the conjugation of modified xenobiotics by transferases
like glutathione s-transferases (GSTs) and UDP-glucuronosyl
transferases, which normally results in less active metabolites that
are also more soluble in water [1]. Drug transporters such as the
ATP-binding-cassette (ABC) superfamily comprise Phase III of the
detoxification pathway. They eliminate and distribute the less
active, more soluble products from Phase II metabolism [1]. The
synthesis of several Cyp enzymes is induced in response to specific
drugs (naptoflavone, PCN) or naturally occurring molecules
(bergamottin, paradisin-A). In some cases the enzyme activity is
also modified by interaction with the drug. As changes in Cyp
activity will affect the metabolism and elimination of various
drugs, understanding and identifying genetic factors that can
modify the detoxification response is especially important when
using drugs with noticeable side-effects, with small therapeutic
windows or necessary to treat critically ill patients.
The product of the retinoblastoma gene (pRB) and its two
related proteins, p107 and p130, control the transition between
G1 and S phase, thus preventing abnormal cell proliferation. They
function by interacting with the E2F family of transcription
factors, which in turn regulate multiple genes essential to progress
through the G1-S phase. Two groups of factors can be identified
within the mammalian E2F family, according to their biochemical
properties, effects of target genes, and expression through the cell
cycle: E2F1-2-3 in one hand and E2F4 through E2F8 on the other
(reviewed in [2],[3]. The work of many groups indicate that pRb
proteins binding to E2F factors either prevents E2F-dependent
transcriptional activation or indeed promotes active repression by
recruiting chromatin remodeling complexes and histone modifying
activities to the promoter, thus effectively blocking S-phase
progression and suppressing undue cell proliferation. However,
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while E2F1, 2 and 3 were originally classified as transcriptional
activators by in vitro assays, we have recently reported a role of
E2F1, 2 and 3 and pRb in transcriptional repression, cell cycle exit
and cell survival [4].
The association between pRb proteins and E2Fs is normally
regulated by cyclin-dependent phosphorylation. However, exog-
enous factors such as viral oncoproteins are able to disrupt the
pRb/E2F complexes, thus their expression results in uncontrolled
proliferation and/or tumorigenesis. In particular, the large T
antigen (TAg) encoded by Simian Virus 40 (SV40) has been shown
to bind and inactivate members of the pRb pathway, resulting in
upregulation of E2F proteins and E2F activity, with the
subsequent induction of cellular proliferation and tumorigenesis
in different systems, both in vivo and in vitro ([5,6] [7]). TAg binds
the pRb proteins through its LXCXE peptide motif, and
mutations in TAg altering or eliminating the LXCXE domain
fail to interact with the pRb proteins and to induce cell
proliferation. In addition to its role inducing cell proliferation
and tumorigenesis, we have previously shown that, when
expressed ectopically in intestinal enterocytes, TAg also downreg-
ulates the endogenous and constitutive RNA levels of multiple
detoxification components from Phases I, II and III [8]. This effect
requires an intact LXCXE motif in TAg, suggesting that perhaps
the transcription of detoxification components normally requires
pRb proteins. We have explored this hypothesis and confirmed
that pRb is required to achieve normal levels of detoxification
enzymes and, furthermore, that depletion of activator E2Fs (E2F1-
2-3) seems to play a similar role. Our results are indicative that
both pRb and E2F1-2-3 act as activators of the detoxification
system and have important implications for understanding tumor
progression and tumor treatment.
Results and Discussion
Organisms respond to xenobiotics by deactivating and excreting
those products via a series of enzymes, which, in mammals, are
located mostly in the liver and small intestine. Three sets of enzymes
contribute to the process: Phase I components chemically modify
xenobiotics by the cytochrome P450 (Cyp) superfamily, whose
activity is responsible for almost 75% of the total drug metabolism.
Subsequently, Phase II components, like glutathione s-transferases
(GSTs) and UDP-glucuronosyl transferase (UGTs), conjugate the
modified xenobiotics to render less active metabolites that are also
more soluble in water. Finally, transporter members of the ATP-
binding-cassette (ABC, Phase III) help to excrete the modified
components via urine or bile [9], [10], [11], [12],[13].
The E2F factors regulate multiple genes essential to progress
through S phase, and binding of E2Fs by the retinoblastoma (pRb)
related proteins effectively blocks S-phase progression and
suppresses cell proliferation [3,14,15]. Associations between pRb
proteins and E2Fs are normally regulated by cyclin-dependent
phosphorylation, ensuring a smooth transition through the cell
cycle. Exogenous factors, including viral oncoproteins like SV40 T
antigen (TAg), can disrupt the pRb/E2F complexes, resulting in
upregulation of E2F target genes, uncontrolled proliferation and/
or tumorigenesis both in vivo and in vitro [16], [17], [7]. An
LXCXE peptide motif in TAg is necessary to bind the pRb
proteins and to induce cell proliferation.
In addition to the induction of ectopic proliferation, expression
of TAg results in the mRNA downregulation of detoxification
components from Phases I, II and III in intestinal enterocytes [8].
This effect requires an intact LXCXE motif in TAg, suggesting
that pRb might control the transcription of detoxification
components. To explore this possibility, we examined the RNA
levels of different members of Phases I, II and III in genetic
background devoid of pRb. Conventional inactivation of pRb in
mice results in numerous alterations and null embryos die around
E13.5 [18],[19], [20], hampering the study of possible pRb effects
prior to birth. Nevertheless, pRb-deficient embryos supplied with a
wild-type placenta are viable, but die soon after birth [21]. Using
such mice allowed us to analyze the effects of pRb ablation in
tissues from embryos and newborn mice. At E12.5, the earliest
point analyzed, the endogenous expression of detoxification
components is absent or barely detectable even by in situ
hybridization (http://www.genepaint.org). However, the tran-
scription levels of Cyp2d10 in livers of control embryos generated
from females treated with PCN (pregnanolone-16 alpha-carboni-
trile) an inducer of the detoxification pathway, are substantially
increased, while are not detectable in RBKO littermates (Figure 1a).
Furthermore, removal of pRb in E18.5 liver samples, at which
point endogenous and inducible levels of several detoxification
components are detectable, results in overall reduction of both
endogenous and PCN-induced levels of Phases I, II and III
transcripts, with the exception of Cyp1b1 (Figure 1b).
We analyzed several tissues in newborn mice, and confirmed
that removal of pRb results in a reduction of endogenous Cyp
levels in newborn livers and intestines, while other transcripts used
as control remain unaltered (Figure 2a). This effect was confirmed
in all the tissues expressing Cyps at that specific developmental
stage, including liver, intestine and lungs (Figure 2b). Other tissues
analyzed from E18.5 to newborn mice, including brain, heart and
spleen, did not show detectable RNA levels of members of the
detoxification pathway with or without chemical challenge (data
not shown). Thus, it appears that pRb is required for constitutive
expression and induction of the Cyp pathway.
Next, we examined mice where RB had been conditionally deleted
in the intestinal epithelium (RBKO mice; [4]). We have previously
published the characterization and validation of the global gene
expression profile in villi and crypts from these mice, as well as from
mice lacking all three activator E2Fs (E2F1-2-3 KO (TKO), and mice
lacking both a functional RB and E2F1-2-3 (QKO) [4]). A summary of
the detoxification genes analysis in RBKO background is shown in
Figure 3a and Supplementary Table S1. Overall, the expression
levels of 37.5% of Phase I genes, 57.7% of Phase II genes and 28% of
Phase III genes are reduced in the absence of a functional RB gene.
The expression levels of genes corresponding to Phases I, II and III of
the detoxification pathway are significantly reduced in RBKO villi
samples. This is highly significant, as, overall, only 875 genes (8.1%)
were downregulated 1.5 fold in RBKO background, 827 genes (7.7%)
were downregulated 1.5 fold in TKO villi, and 820 genes (7.6%) were
downregulated 1.5 fold in QKO. The set of genes downregulated in all
RBKO, TKO and QKO backgrounds in villi amounted to 156 (1.4%).
We used the default settings with the DAVID database (http://
david.abcc.ncifcrf.gov) to annotate genes downregulated in each of
the examined backgrounds. In RBKO background, the fourth cluster
(enrichment score 4.87) is made of members of the detoxification
pathway, with p values ranging from 1.7E-9 to 4.6E-2. In TKO
background, the first cluster (enrichment score 5.57) is composed of
members of the P450 pathway, drug metabolism and Gst proteins,
with p values ranging from 3.9E-13 to 3.8E-2. In QKO background,
the 2nd cluster (enrichment score 4.38) is made of members of the
P450 pathway, drug metabolism and Gst proteins, with p values
from 3.4E-12 to 1.3E-2. Finally, the first cluster (enrichment score
5.06) of genes downregulated in all backgrounds is composed of
members of the P450 pathway, drug metabolism and Gst proteins,
with p values from 1.1E-12 to 2.2E-3.
To confirm the reduced expression of detoxification genes in
RBKO background, we analyzed RNA villi samples by Real Time
Retinoblastoma Regulates a Detoxification Pathway
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PCR analysis (Figure 3b). With the exception of Gst theta 1, these
experiments confirm that the absence of pRb results in
downregulation of almost all detoxification genes tested and,
indeed, values obtained by microarray analysis correlate very well
with those obtained by Real Time PCR (Figure 3c). In contrast to
the Cyp pathway, canonical E2F target genes were strongly
upregulated in villi of RBKO mice (Figure 3d) and [4].
Many of the effects attributed to pRb in controlling the cell
cycle are mediated through its interaction with E2F transcription
factors. In the classic view of cell cycle control, pRb and activator
E2Fs (E2F1-2-3) play antagonistic roles, and thus we examined the
possible role of E2F1, 2 and 3 in regulating the levels of
detoxification genes. Microarrays comparing intestinal villi from
mice lacking functional E2F1, E2F2 and E2F3 genes in the
intestinal epithelium (triple KO or TKO mice) and control
littermates [4] were examined for effects on the detoxification
pathways. We found that the expression of genes from Phases I
and II of the detoxification pathway is significantly reduced in villi
of TKO mice, while Phase III is only marginally affected. Overall,
the expression levels of 37.5% of Phase I genes, 53.8% of Phase II
genes and only 8% of Phase III genes were reduced in the TKO
villi (Figure 4a and Supplementary Table S1). These results
suggest that pRb and E2F1-2-3 do not function antagonistically,
but rather are likely components of a common mechanism
impinging on the control of drug metabolizers.
These results were somewhat surprising as, in the classical view
of cell cycle control, pRb and E2Fs play antagonistic roles and
pRb has been shown to negative regulate E2F activity. However,
we have recently reported a coordinated role of pRb and E2F1-2-3
in transcriptional repression, cell cycle exit and cell survival [4].
Therefore we evaluated expression of detoxification genes in villi
samples from mice lacking pRb as well as E2F1, 2 and 3 (QKO
mice). The overall pattern mirrors the ones obtained with RBKO
and TKO samples. The expression levels of 37.5% of Phase I
genes, 46% of Phase II genes and 12% of Phase III genes were
reduced in villi in the absence of RB and E2F1, 2 and 3 genes
(Figure 3a and Supplementary Table S2). Real Time PCR analysis
of specific genes in TKO and QKO villi (Figure 4b) reiterates that
TKO and QKO samples show a significant reduction in the
expression of detoxification genes, validating the microarray
results (Supplementary Tables S2 and S3). These results indicate
that E2F1-2-3 and pRb cooperate to positively control the
transcriptional levels of detoxification genes. At this point we do
not know if pRb/E2F complexes contribute directly or indirectly
to control the detoxification pathway.
To determine if the observed changes in mRNA abundance are
reflected in protein levels, we analyzed the levels of Cyp3A
proteins, one of the most important subfamilies involved in the
metabolism of xenobiotics, in intestinal and hepatic samples. All
samples tested, including newborn intestines and livers as well as
Figure 1. Impaired detoxification response in livers lacking pRB in the presence or absence of chemical challenge. Conventional RB
+/- females pregnant from RB +/- males were injected with PCN or DMSO -as control- 24 hours prior to sacrifice. RNAs were obtained from livers of
embryos at the indicated times and the corresponding cDNAs were analyzed. a) Unlike the control counterparts, E12.5 RBKO embryonic livers did not
show induction of Cyp2d10 by RTPCR upon PCN treatment. Adh was used as normalizing control and samples were repeated in triplicate. RB +/-
embryos showed similar Cyp2d10 levels to those on normal controls. b) Real Time PCR analysis was used to determine the levels of Phase I, Phase II
and Phase III components in E18.5 livers. Downregulation of most detoxification genes (Phases I, II and III) was observed both, with or without PCN
induction in RBKO background.
doi:10.1371/journal.pone.0026019.g001
Retinoblastoma Regulates a Detoxification Pathway
PLoS ONE | www.plosone.org 3 October 2011 | Volume 6 | Issue 10 | e26019
murine adult villi, showed a considerable decrease in Cyp3A
proteins in the absence of pRb (Figure 4c). Furthermore, removal
of either pRb or E2F1-2-3 leads to decreased Cyp3A protein levels
in the intestinal epithelium of adult mice (Figure 4d). Thus,
transcriptional downregulation of Cyp3A correlates with reduction
in protein levels in intestinal and hepatic tissues.
Our results demonstrate that both pRb and one or more of the
activator E2Fs (E2F1-3) are required for basal expression and
xenobiotic induction of several members of the detoxification
pathway. Active pRb controls cell proliferation by negatively
regulating the activator E2Fs (E2F1-3). Thus, ablation of pRb
leads to E2F-dependent gene transcription and cell proliferation.
We have recently shown that both pRb and the activator E2Fs are
also required to establish repression of E2F-dependent transcrip-
tion as progenitor cells exit the cell cycle and differentiate [4].
Under these conditions other RB family members cannot
compensate for pRb loss, suggesting that pRb-E2F1-3 complexes
must first bind E2F-dependent promoters prior to the establish-
ment of the permanent repressing complex, which consists of
p130-E2F4. Furthermore, under some stress conditions such as
DNA damage, pRb, and not p107 or p130, is involved in blocking
the cell cycle. Perhaps tissues respond to chemo- or genotoxic
stress by inducing pRb, which, in cooperation with the activator
E2Fs, blocks cell proliferation and induces the detoxification
response. This model suggests that the loss of pRb function during
tumorigenesis may have effects on the ability of tumor cells to
metabolize and eliminate toxins or to properly metabolize
anticancer drugs. Specifically, our model would predict that
compounds rendered less toxic by the detoxification pathway
would be more genotoxic in RBKO cells. In fact, RBKO liver cells
are more susceptible to tumorigenesis after treatment with
aflatoxin B1, a drug converted to less toxic products by P450
enzymes [22]. Similarly, our model predicts that cancer treatment
with drugs activated by the P450 pathway (such as tamoxifen)
would not be as effective in RB null background. Consistent with
this, RB deficiency is associated with recurrence of breast cancer
following tamoxifen therapy (reviewed in [23]). Thus, the RB
status impinges on the response to cytotoxic and therapeutic
agents used in cancer treatment [24], reviewed in [23]. In
agreement with this view, intestinal crypts lacking either pRb or
E2F1-2-3 show increased DNA damage [4], perhaps due to a
defect in the detoxification process caused by the absence of either
Figure 2. Phase I mRNA components are significantly reduced in several newborn tissues in the absence of pRb. a) RNAs from
intestines or livers of newborn mice were converted to cDNAs and analyzed by RTPCR with probes specific for different genes. A reduction of Phase I
transcripts was observed in RBKO samples in contrast with control samples, while no changes were observed in several other genes tested. Adh levels
are used as endogenous controls. b) RNAs from newborn tissue samples were analyzed by Real time PCR, indicating that Cyp3A11 and Cyp3a25
mRNAs decrease substantially in samples lacking a functional RB gene in all tissues tested: liver; small intestine and lungs. All samples were
normalized against Rpl5 and compared against those present in control small intestines.
doi:10.1371/journal.pone.0026019.g002
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regulator. A better understanding of the interactions between pRb,
E2Fs and drug metabolizing enzymes could yield valuable insights
to design more efficient cancer treatments as well as to help
minimize adverse reactions to multiple pharmacological substanc-
es in genetically diverse patients.
Materials and Methods
Ethics statement
The protocols used for handling mice were approved by the
Institutional Animal Care and Use Committees of the University
of Pittsburgh (Protocol number 0805624) and the Ohio State
University (Protocol number 2007A0239). All animal work was
conducted according to relevant national and international
guidelines. Mice were maintained in Animal Facilities according
to University regulations and policies, without any dietary
restrictions. Routine screens for mouse pathogens were negative.
Production and maintanance of genetically altered mice
Generation of the conventional or conditionally inactivated
alleles for RB, E2F1, E2F2 and E2F3 has been described [4].
Standard genetic crosses were performed to obtain mice lacking
various genes in the intestinal epithelium (Rbf/f or RBKO; E2F1-/-,
E2F2 -/-, E2F3f/f or TKO; Rbf/f, E2F1-/-, E2F2 -/-, E2F3f/f or
QKO). The genotype of each mice or embryo was determined by
PCR analysis using DNA samples from murine tails and specific
primers [4].
Microarray analysis
The Affymetrix mouse whole genome chip consisting of 21,635
unique genes was used for microarray analysis. All microarray
data is MIAME compliant and had been deposited at the Gene
Expression Ommibus at the National Center for Biotechnology
Information under accession number GSE16454, as described in
our previous publication [4]. We focused on probes for genes
belonging to Phase I (Cyp genes), Phase II (Gst, Ugt genes) and
Phase III (Abc, Slc and Slco genes) of the detoxification pathway.
The total number of genes which were 1.5 fold up or down within
an individual detoxification group was evaluated. To be included
in the analysis, an upregulated gene had to be present in all the
three replicates of the experimental class (RBKO, TKO or QKO)
and a downregulated gene had to be present in all the three
replicates of the control class (control mice injected with b -
naptoflavone).
Figure 3. Transcriptional downregulation of members of the detoxification pathway in villi of RbKO mice. a) Microarray values
obtained from RBKO villi were compared to corresponding ones from control littermates. The percentage of genes up- or downregulated 1.5 fold
within each specific group is represented, indicating a clear downregulation of the detoxification genes in the absence of a functional pRb product. b)
Confirmation of gene downregulation by Real Time PCR analysis. Adult villi RNAs from control and RBKO mice were subjected to Real time PCR
analysis with primers for specific genes of the detoxification pathway. The results were normalized against endogenous controls (Adh and/or Rpl5). c)
Comparison between levels of detoxification components in RBKO versus control villi as observed in microarray or Real Time PCR analysis. d)
Downregulation of detoxifying components in villi lacking pRb is in contrast with the upregulation observed in E2F target genes (TS and DHFR). Real
Time PCR analysis revealed that E2F target genes were increased in RBKO villi, while Cyp3a25 levels showed a drastic reduction. The values represent
the average of three independent samples.
doi:10.1371/journal.pone.0026019.g003
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RNA obtention and transcriptional analysis
RNA was collected with either an RNAeasy kit (Qiagen, Valencia,
CA, USA) or using the RNA-Bee method (Tel-Test, Friendswood,
TX, USA). Synthesis of cDNA, RTPCR and real time PCR analysis
have been described [8]. Each determination for real time analysis
was carried out at least in triplicate and was considered valid only if
the standard deviation was no higher than 0.3, and that the results
shown are representative examples of at least two sets of treatments.
Primers specific for each particular gene are detailed as follows:
Cyp1a1 (59- GACCCTTACAAGTATGTCGT/59-GGTAT-
CCAGAGCCAGTAACCT), Cyp1b1 (59-GCAACTTCAGC-
AACTTCGTTCTG/59-CGGGTATCTGGTAAAGAGGATG-
AG), Cyp2c55 (59-AATGATCTGGGGGTGATTTTCAG/59-
GCGATCCTCGATGCTCCTC), Cyp2d10 (59-GGCAGAGA-
TAGAGAAGGTAAAGGGG/59-GACAGCATTGGTGTAG-
GGCATAC), Cyp3a11 (59-GGAAAGCCGCCTGGATTCTA-
AG/59-ATGCTGCCCTTGTTCTCCTTGC), Cyp3a25 (59-C-
CGTTACTTGGCACCATTTT/59-GTCTTTCATGCTGAT-
GGGCT), Cyp4f13 (59- CGACAGCAACTGCCAAGAGT/59-
CAGTGAGATAGTACAGGAGGTCC), Gstm1 (59-CCTGCC-
CACGTTTCTCTAG/59-CGTGTAGCAAGGGCCTACTT-
G), Gst theta 1 (59-TGTGTGAGAGTGTGGCTATCTTGC/
59TTATGATGAGGTCAGCAGGGGGAC), Mrp2 (59-ACGG-
TCATCACTATCGCACACAGG/59-TTGCTTGAGCCTTA-
GAGTTTGAGG), Rpl5 (59-CCAAACGATTCCCTGGTAAT-
GAC/59-GACGATTCCACCTCTTCTTCTTCAC).
Figure 4. Downregulation of detoxification genes in villi lacking functional pRb and/or E2F1-2-3 proteins. a) Samples from villi or
crypts of RBKO; TKO or QKO mice were compared to corresponding ones from control b-NF-injected mice. The percentage of genes downregulated
1.5 fold versus the control is represented within each specific group of detoxification genes, indicating a clear reduction of the detoxification pathway
in the b) Confirmation of gene downregulation by Real Time PCR analysis of drug metabolizing enzymes in TKO and QKO villi samples in comparison
to values obtained by microarray. Values represent the levels observed in TKO or QKO mice versus control mice. Samples were normalized against an
endogenous control (Adh and/or Rpl5). c) Cyp3A protein levels decrease in samples lacking pRb. RIPA-extracted protein extracts were prepared from
intestines or livers of newborn mice, or from adult fractionated intestines containing villi and crypts as indicated. Control RB +/+; experimental RB -/-
and positive control samples -from adult mouse liver- are indicated. Following SDS-PAGE gels, western blot analysis with anti-Cyp3a antibody
indicates a substantial decrease in Cyp3A levels in all samples lacking a functional pRb. d) Removal of either pRb or E2F1-2-3 results in reduced levels
of Cyp3A protein in adult intestinal samples. RB +/+ (control); RB -/- (RbKO); E2F1 -/-; E2F2 -/-; E2F3 loxP/loxP (TKO) and positive control (adult liver)
samples are indicated.
doi:10.1371/journal.pone.0026019.g004
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Induction of the detoxification response in mouse
embryos
A line containing a conventional inactivation of RB [18] was
obtained from Jackson Labs. RB +/- females pregnant from RB
+/- males were injected at E11.5 days with either PCN
(pregnenolone-16 alpha-carbonitrile; 40 mg/kg) or with DMSO
as a control. Embryonic livers were subsequently collected at
E12.5 days and processed for RNA extraction. To allow RB -/-
embryos to survive after E13.5, we used RB loxP/loxP conditional
knockout and Mox2 +/cre transgenic mice to supply pRb-
deficient embryos with wild-type placentas, as described in [25].
Pregnant females were injected with PCN one day prior to
sacrifice, and the livers or intestines of E18.5 day embryos were
dissected and processed to obtain either RNA or proteins using
standard methods.
Tissue manipulation and protein analysis
Obtention of intestinal fractions enriched for villi and/or crypts
has been described [26]. Protein extraction with RIPA buffer (PBS
1x, NP-40 1%, Sodium deoxycholate 0.5%, SDS 0.1%) in the
presence of protease inhibitors and western blot analysis were
performed using standard techniques. Cyp3a L-14 (Santa Cruz
Biotechnology Inc.), an antibody detecting several Cyp3A
submembers, was used in these experiments.
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